Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

QualityStocksNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Adds Dr. Brian O’Connor to Advisory Board

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning announced the addition of Dr. Brian O’Connor, a consultant in respiratory medicine, to its advisory board. Per the update, O’Connor is a clinical expert in the areas of asthma, chronic obstructive pulmonary disease (“COPD”), allergic disease and lung cancer. He is also an active clinical researcher committed to investigating new treatment strategies in airways disease. “Dr. O’Connor brings a great reputation of clinical excellence and scholarly research,” Dr. Lui Franciosi, CEO of Veritas, stated in the news release. “He will advise us on how to best position the Company’s therapeutic cannabis strains in medical practice as well as assist scientists at our research arm, Cannevert Therapeutics Ltd., with their current research projects.”

To view the full press release, visit

Let us hear your thoughts: Veritas Pharma Inc. Message Board

About Veritas Pharma Inc.

Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through its 80% owned Cannevert Therapeutics Ltd. (“CTL”), is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect CTL’s IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets. For more information, visit the company’s website at

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
480.374.1336 Office
[email protected]

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished:

This post first appeared on Monaker Group, Inc. (MKGI) Carves Niche In Explosi, please read the originial post: here

Share the post

QualityStocksNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Adds Dr. Brian O’Connor to Advisory Board


Subscribe to Monaker Group, Inc. (mkgi) Carves Niche In Explosi

Get updates delivered right to your inbox!

Thank you for your subscription